Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed to support the early detection and staging of cognitive impairment and dementia, leading to appropriate additional testing for the clinical, biological diagnosis and treatment of dementias such as AD. [Read more…] about Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia
For the past several decades, psychedelics have been widely stigmatized as dangerous illegal drugs. But a recent surge of academic research into their use to treat psychiatric conditions is spurring a recent shift in public opinion.
Psychedelics are psychotropic drugs: substances that affect your mental state. Other types of psychotropics include antidepressants and anti-anxiety medications. Psychedelics and other types of hallucinogens, however, are unique in their ability to temporarily induce intense hallucinations, emotions and disruptions of self-awareness. [Read more…] about Mapping ‘psychedelic trips’ in the brain to better direct their therapeutic effects
Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found a ready market in pharmaceutical companies interested in assessing how their experimental brain therapies are working. Now Beacon Biosignals has something else: $27 million in financing. [Read more…] about Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform
In news sure to excite even the most melancholy of artificial intelligence-powered chatbots, mental health platform Woebot has closed its series B funding round with a whopping $90 million. [Read more…] about AI-powered Woebot raises $90M to scale up digital self-therapy platform
The digital health ecosystem has swelled to encompass a broad range of products over the years.
On one end of the spectrum is software-as-medical-devices (SaMD) and prescription digital therapeutics, product categories for which a comprehensive regulatory strategy and engagement with the FDA are mandatory. On the other are wellness apps and other low-risk digital tools that likely spend more time worrying about oversight from the Federal Trade Commission than the health regulator. [Read more…] about Tip for digital health start-ups: To navigate regulatory gray areas, “engage early and engage often” with the FDA
Founded in 2012, Happify is best known for digital programs that provided automated self-guided support across various areas of mental health and wellness, such as stress management for employees or health plan members. Should the user need additional support, the platform can also facilitate a referral to third-party coaching, therapy, telemedicine or other available resources. [Read more…] about Happify Health raises $73M to deepen partnerships with pharmaceutical companies and insurance payers